Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative Nivolumab With or Without Relatlimab in Resectable HCC
NCT04658147Phase 1Active, not recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- May 2021
- Primary completion
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in hepatocellular carcinoma (HCC) comparing Arm A - Nivolumab with Arm B - Nivolumab and Relatlimab (2 arms). Primary endpoint: Number of Patients Precluded From Surgery at 2 months. Started May 2021; status: active, not recruiting.
02
Drugs
nivolumabrelatlimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04658147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04658147.